WO2019204505A3 - Modulateurs de k-ras avec une fraction de sulfonamide de vinyle - Google Patents

Modulateurs de k-ras avec une fraction de sulfonamide de vinyle Download PDF

Info

Publication number
WO2019204505A3
WO2019204505A3 PCT/US2019/027959 US2019027959W WO2019204505A3 WO 2019204505 A3 WO2019204505 A3 WO 2019204505A3 US 2019027959 W US2019027959 W US 2019027959W WO 2019204505 A3 WO2019204505 A3 WO 2019204505A3
Authority
WO
WIPO (PCT)
Prior art keywords
sulfonamide moiety
vinyl sulfonamide
ras
compounds
ras modulators
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2019/027959
Other languages
English (en)
Other versions
WO2019204505A2 (fr
Inventor
Anjali Pandey
Swapan Kumar Samanta
Athisayamani Jeyaraj DURAISWAMY
Anna E. Maciag
David Turner
Matthew Alexander James Duncton
Vandana KUMARI
Adam R. Renslo
Eddy Low
Christopher BRASSARD
Holly V. ADCOCK
Daniel HAMZA
Stuart T. ONIONS
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California Berkeley
University of California, San Diego
Leidos Biomedical Research Inc
Theras Inc
Original Assignee
University of California Berkeley
University of California, San Diego
Leidos Biomedical Research Inc
Theras Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California Berkeley, University of California, San Diego, Leidos Biomedical Research Inc, Theras Inc filed Critical University of California Berkeley
Publication of WO2019204505A2 publication Critical patent/WO2019204505A2/fr
Publication of WO2019204505A3 publication Critical patent/WO2019204505A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
    • C07D207/48—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

L'invention concerne des composés comprenant une fraction sulfonamide de vinyle. L'invention concerne également des compositions pharmaceutiques comprenant de tels composés, et des procédés d'utilisation de tels composés et compositions pharmaceutiques pour inhiber le traitement post-traduction de précurseurs de K-Ras, et pour traiter des troubles chez un sujet en ayant besoin.
PCT/US2019/027959 2018-04-18 2019-04-17 Modulateurs de k-ras avec une fraction de sulfonamide de vinyle Ceased WO2019204505A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862659607P 2018-04-18 2018-04-18
US62/659,607 2018-04-18

Publications (2)

Publication Number Publication Date
WO2019204505A2 WO2019204505A2 (fr) 2019-10-24
WO2019204505A3 true WO2019204505A3 (fr) 2019-11-28

Family

ID=66380207

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2019/027959 Ceased WO2019204505A2 (fr) 2018-04-18 2019-04-17 Modulateurs de k-ras avec une fraction de sulfonamide de vinyle

Country Status (2)

Country Link
TW (1) TW202012396A (fr)
WO (1) WO2019204505A2 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12012403B2 (en) 2021-08-18 2024-06-18 Chemocentryx, Inc. Aryl sulfonyl compounds as CCR6 inhibitors
US12018016B2 (en) 2021-08-18 2024-06-25 Amgen Inc. Aryl sulfonyl (hydroxy) piperidines as CCR6 inhibitors

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11458149B1 (en) 2019-05-31 2022-10-04 Ikena Oncology, Inc. TEAD inhibitors and uses thereof
BR112021024108A2 (pt) 2019-05-31 2022-03-22 Ikena Oncology Inc Inibidores de tead e usos dos mesmos
CN115916194A (zh) 2020-06-18 2023-04-04 锐新医药公司 用于延迟、预防和治疗针对ras抑制剂的获得性抗性的方法
EP4208261A1 (fr) 2020-09-03 2023-07-12 Revolution Medicines, Inc. Utilisation d'inhibiteurs de sos1 pour traiter des malignités à mutations de shp2
US20240066027A1 (en) * 2020-12-03 2024-02-29 Domain Therapeutics Novel par-2 inhibitors
KR102532692B1 (ko) * 2021-03-15 2023-05-16 (주)피알지에스앤텍 신경섬유종증 2형 증후군 예방 또는 치료용 조성물
EP4536634A4 (fr) * 2022-07-21 2026-04-01 Univ California Composés inhibiteurs de la prostaglandine e synthase 3 (ptges3)

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3526638A (en) * 1967-10-05 1970-09-01 Smithkline Corp Substituted 3,4-dihydro-1h-2,1,5-benzothiadiazocine-2,2-dioxides
WO2005073198A1 (fr) * 2004-01-16 2005-08-11 Wyeth Inhibiteurs a base de sulfonamides heterocycliques de la production des beta-amyloides contenant un azole
WO2007060215A2 (fr) * 2005-11-24 2007-05-31 Dompe' Pha.R.Ma S.P.A. Dérivés (r)-arylalkylaminés et compositions pharmaceutiques contenant ceux-ci
WO2008075070A1 (fr) * 2006-12-21 2008-06-26 Astrazeneca Ab Dérivés de sulfonamide à usage thérapeutique en tant qu'inhibiteurs de synthase d'acides gras
US20140288045A1 (en) * 2013-03-15 2014-09-25 Araxes Pharma Llc Covalent inhibitors of kras g12c
WO2014152588A1 (fr) * 2013-03-15 2014-09-25 Araxes Pharma Llc Inhibiteurs covalents de k-ras g12c
WO2016179558A1 (fr) * 2015-05-06 2016-11-10 The Regents Of The University Of California Modulateurs de k-ras
WO2017066193A1 (fr) * 2015-10-15 2017-04-20 Princeton Drug Discovery, Llc Nouveaux inhibiteurs de protéines kinases

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3526638A (en) * 1967-10-05 1970-09-01 Smithkline Corp Substituted 3,4-dihydro-1h-2,1,5-benzothiadiazocine-2,2-dioxides
WO2005073198A1 (fr) * 2004-01-16 2005-08-11 Wyeth Inhibiteurs a base de sulfonamides heterocycliques de la production des beta-amyloides contenant un azole
WO2007060215A2 (fr) * 2005-11-24 2007-05-31 Dompe' Pha.R.Ma S.P.A. Dérivés (r)-arylalkylaminés et compositions pharmaceutiques contenant ceux-ci
WO2008075070A1 (fr) * 2006-12-21 2008-06-26 Astrazeneca Ab Dérivés de sulfonamide à usage thérapeutique en tant qu'inhibiteurs de synthase d'acides gras
US20140288045A1 (en) * 2013-03-15 2014-09-25 Araxes Pharma Llc Covalent inhibitors of kras g12c
WO2014152588A1 (fr) * 2013-03-15 2014-09-25 Araxes Pharma Llc Inhibiteurs covalents de k-ras g12c
WO2016179558A1 (fr) * 2015-05-06 2016-11-10 The Regents Of The University Of California Modulateurs de k-ras
WO2017066193A1 (fr) * 2015-10-15 2017-04-20 Princeton Drug Discovery, Llc Nouveaux inhibiteurs de protéines kinases

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
DATABASE REGISTRY [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 10 August 2010 (2010-08-10), XP002792953, retrieved from STN Database accession no. 1235624-64-2 *
DATABASE REGISTRY [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 2 November 2008 (2008-11-02), XP002792950, retrieved from STN Database accession no. 1069483-13-1 *
DATABASE REGISTRY [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 27 May 2004 (2004-05-27), XP002792951, retrieved from STN Database accession no. 686272-37-7 *
DATABASE REGISTRY [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 3 November 2008 (2008-11-03), XP002792952, retrieved from STN Database accession no. 1069948-57-7 *
DATABASE REGISTRY [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 4 November 2008 (2008-11-04), XP002792949, retrieved from STN Database accession no. 1070688-79-7 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12012403B2 (en) 2021-08-18 2024-06-18 Chemocentryx, Inc. Aryl sulfonyl compounds as CCR6 inhibitors
US12018016B2 (en) 2021-08-18 2024-06-25 Amgen Inc. Aryl sulfonyl (hydroxy) piperidines as CCR6 inhibitors

Also Published As

Publication number Publication date
TW202012396A (zh) 2020-04-01
WO2019204505A2 (fr) 2019-10-24

Similar Documents

Publication Publication Date Title
EP3781564A4 (fr) Composés pour le traitement d'un cancer
WO2018195439A3 (fr) Modulateurs de k-ras
WO2016179558A8 (fr) Modulateurs de k-ras
MX2019003938A (es) Compuestos espirociclicos.
MX392829B (es) Analogos sinteticos de las ecteinascidinas y su uso como agentes antitumorales
WO2020086857A8 (fr) Modulateurs et inhibiteurs de wdr5
EP4438124A3 (fr) Méthodes de traitement de tumeurs de repos surrénales testiculaires et ovariennes
EP4025590A4 (fr) Procédés et compositions pour le traitement du cancer
WO2020055643A3 (fr) Composés, compositions et méthodes de traitement ou de prévention de cancers induits par her
SA519402288B1 (ar) مركب بيريميدين واستخداماته الصيدلانية
EP3939610A4 (fr) Composition pharmaceutique combinée pour le traitement du cancer du poumon à petites cellules
EP4339192A3 (fr) Composés et compositions pour le traitement du cancer
IL290177A (en) History of 4,2,1-oxadiazol-5-one for cancer therapy
MX2021012096A (es) Compuestos de indenilo, composiciones farmaceuticas y usos medicos del mismo.
EP3970745A4 (fr) Composition pharmaceutique pour le traitement de tumeurs
EP3962919A4 (fr) Composés pour traiter le cancer
EP3909597A4 (fr) Composition pharmaceutique permettant de prévenir ou de traiter le cancer contenant un oligopeptide en tant que principe actif
EP4074316A4 (fr) Composition pharmaceutique pour la prévention ou le traitement du cancer
EP3994269A4 (fr) Compositions pharmaceutiques, kits et méthodes de traitement de tumeurs
MX2019009199A (es) Composiciones y métodos para modular ppp2r1a.
WO2021102359A3 (fr) Inhibiteurs de taspase1 et leurs utilisations
EP3984553A4 (fr) Composition pour prévenir ou traiter le cancer
EP3856784A4 (fr) Combinaison pharmaceutique pour le traitement du cancer
WO2020198567A8 (fr) Dérivés de quinoléine et leur utilisation pour le traitement du cancer
EP4085908A4 (fr) Combinaison pharmaceutique destinée à traiter des tumeurs et son application

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19721498

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 19721498

Country of ref document: EP

Kind code of ref document: A2